1283 results about "Insulin" patented technology

A method for guiding a user to select a dose of insulin, including the steps of calculating a firsts pecific dose of insulin by applying information provided by the user to an insulin dose calculation algorithm, wherein such information includes at least the user's current blood glucose level and the user's desired blood glucose level, calculating at least a second specific dose of insulin that is different from the first specific dose, and presenting to the user a range of doses comprising at least two of the specific doses.

An infusion system that includes a watch controller device and a communication system to transmit the communications from the watch controller device to an infusion device pump that controls delivery of fluids to the user's body. More particularly, these apparatuses and methods are for providing convenient monitoring and control of the infusion pump device in determining the appropriate amount of insulin to deliver.

The invention provides a drug-oligomer conjugate having the following general formula:wherein D is a therapeutic drug moiety; H and H' are each a hydrophilic moiety, independently selected from the group consisting of straight or branched PEG polymers having from 2 to 130 PEG subunits, and sugars; L is a lipophilic moiety selected from the group consisting of alkyl groups having 2-26 carbon atoms, cholesterol, adamantane and fatty acids; o is a number from 1 to the maximum number of covalent bonding sites on H; m+n+p together have a value of at least one and not exceeding the total number of covalent bonding sites on D for the -H', -L and -H-L substituents; the H-L bond(s) are hydrolyzable and the D-L' bond(s), when present, are hydrolyzable; the conjugate being further characterized by one of the following: (i) m is 0 and p is at least 1; (ii) n is 0 and p is at least 1; (iii) m and n are each 0 and p is at least 1; (iv) p is 0 and m and n are each at least 1. The therapeutic drug moiety is preferably a therapeutic protein or peptide, preferably insulin or a functional equivalent thereof.

The method and system for managing a patient's blood glucose level predicts an insulin dosing rate to bring a patient's blood glucose level into a preferred target range within a predetermined time interval. The system includes a processor which actuates a blood glucose computer program to measure and predict the patient's blood glucose level. An input mechanism allows for insertion of a preferred target range of the patient's blood glucose level and further permits input of various patient data parameters. The processor calculates the optimum insulin dosing rate for the patient based upon the type of insulin dosing whether it be intravenous dosing and / or subcutaneous dosing. A display mechanism displays the patient dosing parameters and an alarm mechanism alerts a user when the patient's blood glucose level is outside of the preferred patient blood glucose target range.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

Methods and apparatus are provided for determining a diabetic patient's carbohydrate to insulin ratio (CIR), carbohydrate to blood glucose ratio (CGR), and insulin sensitivity factor (ISF) using the patient's record of blood glucose readings, carbohydrate consumption and insulin doses. The method provides the sensitivity factors that best account for the patient's observed blood glucose changes by linear regression of appropriately transformed variables. An apparatus that can collect and store the blood glucose readings, insulin dosages, and carbohydrate intake data and process these data according to this invention can generate statistically characterized sensitivity factors to advise the diabetic patient on optimal bolus insulin dosages.

The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.

A safe and effective treatment to curtail and cure autism spectrum disorders has been described in this invention using insulin, IGF-1, with multiple known adjuvant therapeutic agents, as well as other pharmaceutical, biochemical, nurticeuticals, and biological agents or compounds delivered through the olfactory mucosal region of the nose and external auditory meatus.

A method of displaying medical data, particularly data representative of the condition of patients suffering from chronic medical conditions such as asthma, diabetes and hypertension. The display consists of two graphical elements, one of which indicates the current value of a parameter indicative of the patient's condition, this being displayed against another graphical element which represents a model of normality for that patient. The graphical element indicating the current condition may be, for example, a needle, against a scale which is constructed according to the patient-specific model of normality. This is particularly advantageous in the case of displays which have a small display area, such as mobile telephones and PDAs. Other forms of display are disclosed, such as histograms with the display being dynamically colour-coded and auto-scaled, or displays including limits which may vary. Another form of display is also disclosed which illustrates administrations of a pharmacological agent and corresponding measurements of the patient's condition, with a visual link such as colour-coding linking the administration to the corresponding condition measurement. For example several days of insulin administration dosages may be displayed alongside several days of blood glucose measurements, with the administrations colour-coded to the corresponding blood glucose measurement, to assist the patient in determining whether the insulin administration is stably controlling their condition.

Peptide sequences capable of binding to insulin and / or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.

The invention relates to a method of food and insulin dose management for a diabetic subject, comprising:providing an intended insulin unit value or an intended carbohydrate unit value representing the amount of insulin or carbohydrate intended for intake by the subject; anddetermining the balance value of either insulin units or carbohydrate units needed to balance with the provided unit value and maintain blood sugar in the subject in a target blood sugar range.

A fluid delivery device having a self-contained stored energy membrane for expelling fluids at a precisely controlled rate, which is of a compact, laminate construction. The device is of very low profile so that it can conveniently be used for the precise delivery of a small volume of pharmaceutical fluids, such as insulin, morphine and the like, into an ambulatory patient at precisely controlled rates over extended periods of time. The device includes strategically configured, multiple fluid chambers to achieve the maximum possible average percent of extension of the membrane and thereby assure adequate fluid delivery pressure.

This invention discloses compositions of chloroquine-coupled active agents such as therapeutic antibodies or insulin, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the drug is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to a drug directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing the drug for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and antibody or insulin to their site of action.

The invention relates to an inserter for a medical device e.g. an infusion set or the like for intermittent or continuous administration of a therapeutical substance, such as e.g. insulin. The inserter comprises a needle hub comprising an insertion needle and two elastic elements assuring automatic insertion and automatic retraction of the insertion needle. Activation of the first elastic element (11) cause a penetrating member (6A) to be inserted sub-or transcutaneously into the skin of a patient, and the second elastic element (12) cause the penetrating member (6A) to be retracted from the skin of the patient. The first elastic element (11) is in an unloaded state before activation and upon activation the first elastic element (11) energizes the second elastic element (12).

The present invention relates to a process for producing a therapeutic powder formulation, comprising (a) providing an acidic aqueous solution comprising an insulin or analoguc or derivative thereof and an enhancer; (b) adjusting the pH to a pH in the range of 4.5 to 7.4; (c) precipitating a product comprising the insulin or analogue or derivative thereof and the enhancer, wherein the precipitation is performed essentially without evaporation of the solution; and (d) removing the water.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

Peptide sequences capable of binding to insulin and / or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.

A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and / or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body. The composition may further contain one or more of: at least one agent for suppressing inflammation in the body; at least one agent for normalizing or maintaining vascular wall function and structure in the body; at least one agent for normalizing or maintaining function of nerve growth factors and / or neurotropic factors in the body; at least one agent for suppressing toxic metal ionic effects; at least one agent for normalizing or maintaining methyl metabolism in the body; at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and at least one agent for up-regulating activity of heat shock proteins in the body. A method for normalizing impaired neurological function in humans modulating nutrient partitioning in a human involves administering the aforementioned composition to the human, preferably on a daily basis, for a therapeutically effective period of time. Preferably, the method further involves having the human follow a stress reduction program, and / or a cognitive retraining program, and / or a dietary program designed to maximize insulin and glucose metabolism.

The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.

The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.

Peptide sequences capable of binding to insulin and / or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.

The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and / or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-1R kinase inhibitors. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to IGF-1R kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by IGF-1R kinase inhibitors are also provided.

Various embodiments are described and illustrated to calculate an insulin bolus, recommend such bolus, and provide reminder messages for performing an additional glucose test.

The present invention relates generally to an oral drug delivery system which incorporates a therapeutic bioactive agent with biodegradable calcium phosphate particles, the particles then encapsulated by casein. The resulting particles provide a carrier designed to protect the therapeutic agent in the harsh, acidic environment of the stomach before releasing the agent into the small intestine. The therapeutic agent may be any therapeutically effective agent, such as a natural isolate or synthetic chemical or biological agent, such as a therapeutic agent, and in particular, may be a protein or a peptide such as insulin. Also incorporated with the particles may be additional surface modifying agents to assist binding, controlled release, or to otherwise modify the particles. The particles generally support the therapeutic agent to form controlled- or sustained-release particles for the oral or mucosal delivery of the therapeutic agent over time, wherein the therapeutic agent is incorporated into the structure of the particle core, disposed on the surface of the particle, or both.

An injection device with puncture function includes, in a single casing 30, a cylindrical cartridge 11 in which insulin 12 is enclosed, a cartridge holder 14 to which the cartridge 11 is inserted, a needle 16 inserted at a front end 11a of the cartridge 11, a reciprocation means 32 for reciprocating the cartridge 11 toward the needle 16, and an extrusion means 23 for extruding the insulin 12 from a rear end11b of the cartridge 11 toward the needle 16, and the motion speed and the motion amount of the reciprocation means 32 are made variable.

Pharmaceutical dosage forms for oral administration to a patient for the treatment of diabetes, comprising insulin and a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and that result in a lower incidence of vascular diseases associated with the repeated administration of insulin are disclosed. Also disclosed is a method of attenuating the undesirable incidence of diseases associated with chronic dosing of insulin is provided whereby the oral administration to a patient of insulin along with a suitable delivery agent that facilitates the absorption of insulin from the gastrointestinal tract of the patient in a therapeutically effective amount, for treatment of diabetes.